Merck’s WINREVAIR™ Achieves Breakthrough in PAH Treatment, Cutting Mortality Risk by 76%

Merck’s WINREVAIR™ (sotatercept-csrk) has delivered a major breakthrough in pulmonary arterial hypertension (PAH) treatment, showing a 76% reduction in major morbidity and mortality events in high-risk patients. The Phase 3 ZENITH trial, which was stopped early due to overwhelming efficacy, demonstrated that patients treated with WINREVAIR experienced fewer hospitalizations, lung transplants, and deaths compared to those on a placebo. These results were presented at the American College of Cardiology’s Annual Scientific Session and published in the New England Journal of Medicine, reinforcing the drug’s potential to transform PAH management.

This is the second Phase 3 trial confirming WINREVAIR’s efficacy, following the STELLAR study. Merck has already begun working with global regulatory agencies, positioning WINREVAIR as a game-changer for PAH patients. The company also announced the early conclusion of its HYPERION trial, moving directly to final analysis based on positive interim data. With promising results across multiple studies, WINREVAIR is setting a new standard for PAH treatment and patient survival outcomes.